Printed From:

TYPE 2 INFLAMMATION in
ATOPIC DERMATITIs

Atopic dermatitis is a systemic, immune-mediated chronic inflammatory
disease characterized by skin lesions and pruritus1,2

Atopic dermatitis is associated with immune dysregulation and skin
barrier dysfunction influenced by genetic and environmental factors3

Signs and symptoms of atopic dermatitis include4:

Pruritus

Patients with moderate-to-severe atopic dermatitis experience frequent extended periods of itch, which can be severe or unbearable and may be described as pain

Skin lesions

More than 50% of adult uncontrolled moderate-to-severe patients have reported experiencing these symptoms at least 5 days a week:

  • Bleeding
  • Cracking
  • Flaking
  • Dry, rough skin
Aggravation of skin lesions can occur through the itch-scratch cycle5

Moderate-to-severe atopic dermatitis is a chronic condition with
significant emotional effect on patients6

The resulting stigma of atopic dermatitis can affect patients’:

  • Self-esteem
  • Mood
  • Self-confidence
  • Ability to establish and manage relationships
Many aspects of the social and emotional impact of atopic dermatitis
are heightened with increasing age and disease severity6

Allergic comorbidities are common in patients with atopic dermatitis

Early-onset atopic dermatitis is associated with subsequent allergic diseases, including7:

food allergies allergic rhinitis Asthma 
Severity of atopic dermatitis directly correlates
with the severity of comorbidities8
References: 1. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50. 2. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657. 3. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z 4. Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491-498. 5. Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8-13. 6. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226-232. 7. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17-27. 8. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476-486.